Related Experiment Video
Updated: Jul 25, 2025

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Compounded Effervescent Magnesium for Familial Hypomagnesemia: A Case Report
Giada Bennati1, Mario Cirino1, Giulia Benericetti1
1Department of Pharmacy and Clinical Pharmacology, Institute for Maternal and Child Health-IRCCS Burlo Garofolo, 34137 Trieste, Italy.
Familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC) treatment improved with a new effervescent magnesium formulation. This alternative offers better patient compliance and magnesium bioavailability compared to traditional therapies.
Area of Science:
- Nephrology
- Genetics
- Pharmacology
Background:
- Familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC) is a rare genetic disorder caused by CLDN16 or CLDN19 gene mutations.
- Current management lacks specific drug therapies, relying on magnesium supplementation with variable bioavailability and patient compliance.
- Previous treatments using magnesium pidolate and citrate led to adverse effects like diarrhea, reducing adherence.
More Related Videos
Related Concept Videos
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids
However, this neutralization reaction between...
Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Qualitative Analysis
For instance, group IV...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Introduction to Electrolytes
Role of Sodium
One...
Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...

